公开(公告)号：US20130309236A1

公开(公告)日：2013-11-21

申请号：US13956266

申请日：2013-07-31

Applicant: Genentech, Inc.

Inventor： Anan CHUNTHARAPAI ,  Jin K. Kim ,  Leonard G. Presta ,  Timothy Stewart

IPC: C07K16/24

CPC classification number: C07K16/249 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/564 ,  G01N33/6866 ,  G01N2333/56 ,  G01N2800/042 ,  G01N2800/24

Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of TUN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).

Abstract translation: 本发明一般涉及对各种IFN-α亚型具有广泛反应性的中和抗IFN-α单克隆抗体的产生和表征。 本发明还涉及这样的抗-IFN-α抗体在诊断和治疗与TUN-α表达增加相关的疾病中的用途，特别是自身免疫性疾病如胰岛素依赖性糖尿病（IDDM）和系统性红斑狼疮 （SLE）。

公开(公告)号：US20200291119A1

公开(公告)日：2020-09-17

申请号：US16885067

申请日：2020-05-27

Applicant: Genentech, Inc.

Inventor： Doris KIM ,  Terence WONG ,  Anan CHUNTHARAPAI ,  Cherie Louise GREEN

IPC: C07K16/28 ,  G01N33/574

Abstract: The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a N detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry.